Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Post by Goldnboy1on Jun 24, 2023 3:30am
498 Views
Post# 35512608

Next $TRIL?! 10 Bagger Still To Come!!

Next $TRIL?! 10 Bagger Still To Come!!

$ONC has a legit shot at being the next $TRIL.

From the time $TRIL showed promising clinical trials, their stock went from $100m market cap to $2.45B in just 23 months. They were just phase 1. This is phase 3. Which is extremely valuable in terms of costs left to get to market. With shares this tight and a more cost effective path to approval, that is a recipe to out perform $TRIL.

It took just a matter of weeks for $TRIL to go from $100M to $1B. Then Pfizer made a $25m investment as apart of a $117M fundraising at that billion dollar valuation. I believe a similar deal is in the works here. 

Management stating definitive agreement is coming in the next 90 days to complete the trials lines up perfectly with how $TRIL's major announcement played out.

I believe the major circling $ONC will "make the market" over the course of the next 2 months before announcing a big raise in month 3. With just $30m on the balance sheet and a $3m a month burn when not in Phase 3 trials $ONC needs cash, I would say a $50-$100m raise is coming.

Hold on tight, this could go to $15-$20 by September. Much more by end of 2024. 

$60M+ CAD traded on all markets today, or roughly 25% of the float turned over in just one day! Two weeks ago the stock was hardly trading $500k-$1M a day on all markets. That's not a move momentum traders and retails can create, that is special volume. If this volume persists or even increases, as I expect it will. Stock could double from todays close next week with ease!

I took 10,000 shares at open today. Grabbed another 20,000 just before the close today. Bring on the billion dollar valuations!!

GLTA!!

<< Previous
Bullboard Posts
Next >>